靶向乙型肝炎表面抗原的小分子抑制临床相关耐药乙型肝炎病毒
研究在Huh7细胞中评估小分子ZINC20451377对9种临床相关耐药HBV突变体的效果,该分子靶向HBsAg。结果显示其对野生型和所有9种突变体的分泌HBsAg呈剂量依赖性抑制,IC50在低微摩尔范围;但除rtL180M+rtM204V(MV)突变体外,可抑制耐药突变体的HBV分泌。总体效果中等,对MV突变体无效。
要点
- ZINC20451377对WT和9种耐药HBV突变体的分泌HBsAg呈剂量依赖性抑制,IC50在低微摩尔范围。
- 该分子可抑制除MV(rtL180M+rtM204V)突变体外的耐药突变体HBV分泌。
- ZINC20451377总体效果中等,对拉米夫定和恩替卡韦耐药的MV突变体无效。
核心结论
- 小分子ZINC20451377可抑制部分临床相关耐药HBV突变体的HBsAg和病毒颗粒分泌,但总体效果中等,且对MV突变体无效。
研究设计与样本
- 在Huh7细胞中转染对应WT HBV或耐药HBV突变体的1.2× HBV复制子,并给予不同浓度ZINC20451377处理。
- 通过ELISA测定培养上清HBsAg水平以计算ZINC20451377的IC50,并通过免疫捕获分泌病毒颗粒后实时PCR定量病毒颗粒相关DNA来检测HBV分泌。
主要发现
- ZINC20451377对WT HBV和所有9种受试耐药突变体编码的分泌HBsAg呈剂量依赖性抑制,IC50值在低微摩尔范围。
- ZINC20451377抑制耐药突变体的HBV分泌,但携带rtL180M+rtM204V(MV)突变的突变体除外。
局限性
- ZINC20451377总体效果中等,且对MV突变体(拉米夫定和恩替卡韦耐药突变体)无效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently approved oral antivirals for chronic HBV infection target the reverse transcriptase (RT) domain of the HBV polymerase. Emergence of drug resistance has been reported in a small proportion of chronic HBV patients on prolonged treatment with antivirals. We recently reported ZINC20451377, a small molecule targeting hepatitis B surface antigen (HBsAg) that effectively inhibits both WT HBV and tenofovir-resistant HBV. Due to the partial overlap between the RT domain and HBsAg, drug-resistant mutants are associated with corresponding mutations in HBsAg. OBJECTIVES: To evaluate the efficacy of ZINC20451377 against nine clinically relevant drug-resistant HBV mutants that lead to simultaneous mutations in the overlapping HBsAg gene. METHODS: Huh7 cells were transfected with 1.2× HBV replicons corresponding to WT HBV or drug-resistant HBV mutants and treated with different concentrations of ZINC20451377. We assessed the IC50 values of ZINC20451377 for HBsAg levels in the culture supernatants using ELISAs. HBV secretion was measured by immunocapture of secreted virions followed by real-time PCR quantitation of virion-associated DNA. RESULTS: ZINC20451377 led to a dose-dependent inhibition of secreted HBsAg encoded by WT HBV and all nine drug-resistant mutants tested and the IC50 values were in the low micromolar range. ZINC20451377 inhibited HBV secretion from drug-resistant mutants except for mutants harbouring the rtL180M + rtM204V (MV) mutation. CONCLUSIONS: The small molecule ZINC20451377 inhibits HBsAg and virion secretion in some of the clinically relevant drug-resistant HBV mutants. ZINC20451377 has a modest overall effect, and it was not effective against the MV mutants (lamivudine- and entecavir-resistant mutants).
引用
- Kiruthika S, Bhat R, Jayaram B, et al. A small molecule targeting hepatitis B surface antigen inhibits clinically relevant drug-resistant hepatitis B virus. J Antimicrob Chemother. 2022. PMID: 35514268. doi:10.1093/jac/dkac148
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。